Hu, Hongxiang

Why 90% of clinical drug development fails and how to improve it?

Sun, D., Gao, W., Hu, H., & Zhou, S. (2022) · Acta Pharmaceutica Sinica B

Computational Drug Discovery MethodsAnimal testing and alternatives

Cited by 1,763

Lysosomal Degradation Is Required for Sustained Phagocytosis of Bacteria by Macrophages

Wong, C.-O., Gregory, S., Hu, H., Chao, Y., Sepúlveda, V. E., He, Y., Li-Kroeger, D., Goldman, W. E., Bellen, H. J., & Venkatachalam, K. (2017) · Cell Host & Microbe

Immune Response and InflammationInvertebrate Immune Response Mechanisms

Cited by 114

BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

Bal, S., Htut, M., Nadeem, O., Anderson, L. D., Koçoğlu, H., Gregory, T., Rossi, A. C., Martin, T., Egan, D. N., Costa, L., et al. (2023) · Blood

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 59